Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non-Current Deffered Revenue (2024 - 2025)

Historic Non-Current Deffered Revenue for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Q3 2025 value amounting to $3.0 million.

  • Day One Biopharmaceuticals' Non-Current Deffered Revenue fell 352.83% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 352.83%. This contributed to the annual value of $3.2 million for FY2024, which is N/A changed from last year.
  • Day One Biopharmaceuticals' Non-Current Deffered Revenue amounted to $3.0 million in Q3 2025, which was down 352.83% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Non-Current Deffered Revenue ranged from a high of $3.4 million in Q2 2025 and a low of $3.0 million during Q3 2025